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Summary In order to identify drugs active against mutated ras oncogenes we have developed an in vitro assay
employing two clones of the human fibrosarcoma cell-line, HT1080 which carries an N-ras gene mutated at
codon 61. Clone, HT1080scc2, retains the transformed phenotype of the parental line, whilst the other,
HT1081c, is a morphologically flat, non-tumourigenic, revertant with under-representation of the chromosome
carrying the transforming N-ras allele. The clear implication of mutant ras in maintaining the transformed
nature of HT1080scc2 was confirmed when these cells were microinjected with the pan ras neutralising
antibody Y13-259, which resulted in the morphological detransformation of these cells to a phenotype
resembling that of the HT10801c clone. A number of known anti-cancer drugs with modes of action unrelated
to ras function were found to be equipotent against both clones. However, when compounds chosen on the
grounds of their potential selective cytotoxic or differentiating activity were tested some interesting results were
obtained. Thus 8-bromo cAMP affected some morphological detransformation of HT1080scc2 cells and
reduced their colony forming potential. The IMP-dehydrogenase inhibitors, tiazafurin and mycophenolic acid
also flattened the morphology of the transformed clone. Fumagillin, an antibiotic reported to exhibit selective
activity against ras transformed cells showed very marked and selective cytostatic effects against HT1080scc2
cells with IC50 values as low as 1 x 10-"M.
Mutated ras genes are associated with a wide variety of
human tumours (Bos, 1988). Chemical modulation of the
protein products of these oncogenes may lead to the detrans-
formation of such tumours and possibly represent useful
targets for selective anti-cancer chemotherapy. To test this
supposition, compounds that have a modulatory effect on
oncoprotein function need to be identified either through
rational drug design based perhaps on the protein's structure
or by the more random evaluation of compounds of diverse
chemical type for leads with such activity. Both approaches
required biological assays capable ofdetecting this ras-related
detransformation at the cellular level.
Tumour cells that would appear to suit this purpose are
the transformed sub-line, HT1080-scc2 and the revertant sub-
line, HT108001c both derived (Paterson et al., 1987) from the
human fibrosarcoma cell line, HT1080 (Rasheed et al., 1974).
It has been established (Hall et al., 1983; Brown et al., 1984)
that the parental HT1080 line contains an N-ras gene
mutated (Gln-lys) at codon 61 and by Paterson et al. (1987)
that in HT1080scc2, the transformed phenotype is controlled
by the increased dosage of this gene relative to that found in
HT10801c. Such differences in phenotype could be abolished
by transfection of HT10801c with the N-ras oncogene from
HT1080 resulting in retransformation to the HT1080scc2
phenotype. Two distinct cell sublines of the same lineage
would therefore appear to depend only on their relative
mutated-ras-gene dosage for maintenance of these differences.
We reasoned that such cells might also be responsive to other
modulators of ras function and on this basis the assay de-
scribed in the present work was developed and evaluated.
Materials and methods
Cell lines and culture conditions
Transformed and revertant HT1080 sub-lines. HT1080scc2
and HT10801c were obtained from the Institute of Cancer
Research, Chester Beatty Laboratories, Fulham Road,
London. They were maintained routinely in Dulbecco's
Modified Eagle's Medium (DMEM) supplemented with 10%
foetal calf serum (FCS) and 1% penicillin/streptomycin solu-
tion containing 10,000 units per ml. All reagents were
obtained from Gibco Ltd.
Cells were incubated in tissue culture grade plastic vessels
at 37°C in 5% CO2 in air.
Kinetic andmorphological studies
For determining the relative growth rates of the two lines,
cells were plated out in 10 ml complete medium into 25 cm2
tissue culture flasks at a density of 1 x IO0 cells per ml. On
each day for 6 days thereafter cells in three flasks of each line
were trypsinised and the resultant cell suspensions
resuspended in complete medium and counted in a Coulter
counter. Four aliquots from each flask were always counted
three times. The mean number of cells per ml in each group
of three flasks was then calculated for each cell line and
compared.
For morphological studies, flasks containing cells at pre-
and post-confluent stages of growth were taken. The cells
were then either examined directly by phase contrast micro-
scopy or fixed in 3% neutral buffered formalin and stained
either with Giemsa or Crystal Violet prior to microscopical
examination.
To study the colony forming ability of cells under
anchorage independent conditions, cells were grown in
60 mm diameter Petri dishes in 1.5 ml complete culture
medium containing 0.3% agar overlaying a solid 5 ml layer
of 1.8% agar. The cell concentration at the start of each
experiment was 1 x 105 cells per dish. The cultures were
incubated at 37°C in 5% CO2 in air for 14 days and each was
fed with an additional i .5 ml of sloppy agar in complete
medium on day 7. On day 13, 1 ml of 1% p-iodonitro-
tetrazolium violet (INT) was added to each dish. They were
kept at 37°C for a further 24 h prior to examination for
colony formation on day 14.
Microinjection experiments
HTlO8Oscc2 cells grown to sub-confluence on small (35 mm
diameter) Petri dishes were injected intracytoplasmically
either with the pan-anti-ras antibody, Y13-259 (Oncogene
Science) dissolved in phosphate buffered saline to a concent-
ration of 10mg ml-' or with a similar concentration of rat
IgG, control antibody, once daily for 2 days. On day 3 the
test and control cells were examined microscopically for any
change in morphology and their proliferative status was
determined using the bromodeoxyuridine-based, Amersham
Cell Proliferation Kit.
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Compounds tested
The standard anti-cancer drugs tested were, doxorubicin,
cisplatin, 5-fluorouracil, melphalan, 6-mercaptopurine, metho-
trexate and vincristine. Compounds tested on the grounds of
their possible modulatory effects on cell differentiation and/
or on ras function were, 8-bromo cAMP, mycophenolic acid,
tiazofurin, mevinolin and fumagillin. Tiazofurin was obtained
from Parke Davis Pharmaceuticals, Ann Arbor, Michigan,
USA, mevinolin from Merck, Sharp and Dohme, Rahway,
New Jersey, USA and fumagillin from Chinoin Pharma-
ceuticals, Hungary. All other compounds came from Sigma
Chemical Company Ltd., Poole, Dorset, England.
Assaysfor drug activity
Assays for cell proliferation/cytotoxicity were carried out in
tissue culture grade 96-well microtitre plates (Costar Ltd.)
Cells in log growth were added to the plates at a concentra-
tion of 1 x IO0 cells per well on day 0 and serially diluted
drugs were then added on day 1. Plates were then incubated
at 37°C in 5% CO2 in air for a further 4 days.
For quantitation of cell growth, the methylene blue
biomass staining method of Finlay et al. (1984) was used, the
test being read on a Multiscan plate reader at a wavelength
of 620 nm. The morphology of the cells was checked micros-
copically under phase-contrast immediately before fixation
and staining with methylene blue, and by ordinary light
microscopy thereafter. IC50 values for active compounds were
obtained using the computer programme, GS1 and dose-
response slopes were also plotted.
Where compounds were tested for activity in a colony
forming assay the methods used were identical to those des-
cribed earlier except that serially diluted drug was added to
the sloppy agar when the test was set up, and replenished at
the same concentration on day 7. The results were read on
day 14.
Results
Comparative growth andmorphology ofHT1080scc2 and
HT10801c
Growth rates in terms of cell number were similar for both
lines to day 4 but thereafter HT1080scc2 cells continued to
divide to reach saturation densities approximately 2 to 3
times higher than HT10801c by day 5 (Figure 1).
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Figure 1 Comparative growth of HT1080scc2 and the revertant
clone, HT10801c over a 6 day time-course. Both clones were
seeded at a density of 1 x I04 cells per ml on day 0.
Phenotypic differences between the two lines were clearly
evident. HT10801c cells displayed a much flatter morphology
then the transformed cells and only few mitotic cells were
seen in confluent areas of the cultures. HT1080scc2 cells
however continued to divide with numerous mitotic cells
visible after confluence (Figure 2).
Grown under anchorage independent conditions in soft
agar, HT1080scc2 produced several large colonies whereas
HT10801c cells failed to produce any colonies greater than
0.1 mm in diameter (Figure 3).
Effects ofmicroinjection with Y13-259
HT1080scc2 cells microinjected with Y13-259 (Figure 4)
developed a detransformed morphology similar to that of
sub-confluent HT10801c cells. No such alteration in mor-
phology was seen in those cells microinjected with control rat
IgG. Little or no incorporation of bromodeoxyuridine was
seen within the nuclei of cells injected with Y13-259 whilst
those in cells injected with the control antibody were darkly
stained indicative of actively dividing cells.
Effects ofknown anti-cancer drugs on growth andmorphology
IC50 values for inhibition of growth obtained for each drug
against both cell lines are given in Table I. All compounds
were active against both lines with IC50 values ranging
between less than 1 x 10-9 M (vincristine) to 1 x 10-5 M (mel-
phalan). Individual compounds gave similar IC50 values
Figure 2 Comparative morphology of a, HT1080scc2 and b,
HT10801c after 6 days in culture. Note the contact inhibited
flatter morphology of HT10801c relative to the smaller
HT1080scc2 cells which continue to divide, as evidenced by the
large number of raised refractile cells still present on day 6.
Bar = 30 microns.858 D.C. JENKINS et al.
Figure 3 Colony growth of a, HT1080scc2 and b, HT10801c
after 14 days under anchorage independent conditions in soft
agar. Both clones were seeded at an initial density of 1 x 105 cells
per 60 mm dish on day 0. Colonies were stained with INT on day
13. Note the presence of numerous colonies of HT1080scc2
relative to the very few smaller colonies of HT10801c cells.
against both lines. No obvious change in the transformed
morphology of the HT1080scc2 cells towards that of the
revertant HT10801c cells was seen at near- or non-toxic
concentrations of any of the drugs.
Effects ofselected compounds considered likely to affect ras
function
The compounds, 8-bromo cAMP, mycophenolic acid,
tiazofurin, mevinolin and fumagillin were evaluated against
both lines (Table I). 8-bromo cAMP showed only weak
cytotoxicity against either line but at concentrations down to
about 5 x 105 M the compound did exert a morphological
effect on the transformed HT1080scc2 line (Figure 5). At
such concentrations flattening of the cells was seen with
reversion of the transformed phenotype towards the revertant
phenotype of HT10801c. This was associated with cytoplas-
mic spreading, restoration of signs of contact inhibition, and
a marked hypochromicity to Glemsa and crystal violet stain-
ing. At a concentrtation of 1 x 10- M, 8-bromo cAMP also
Figure 4 Effects of cytoplasmic microinjection of monoclonal
antibody Y13-259 on HT1080scc2 cells. Cells in a, were injected
with Y13-259 on days 1 and 2 whilst those in b, were injected
with rat IgGI control antibody. All cells were stained with the
bromodeoxyuridine based Amersham Cell Proliferation Kit on
day 3. Note that cells in a, possess a flat HT10801c-like revertant
morphology and that few nuclei are stained. Cells in b, however
have retained the transformed morphology of HT1080scc2 and
most nuclei are deeply stained, indicative of actively dividing
cells. Bar= 10 microns.
inhibited the ability of HT1080scc2 to form colonies in soft
agar. Cells within the agar remained viable as determined by
tetrazolium dye reduction but were prevented from growth
into colonies.
The IMP dehydrogenase inhibitor, mycophenolic acid was
cytotoxic against both lines with IC_0 values of 7.6 and
5.4 X 10- M against HT10801c and HT1080scc2 respectively.
Some flattening of the scc2 cells was seen but only at concen-
trations where amarked degree of cytotoxicity was also evi-
dent. Tiazofurin showed similar flattening effects on the cells
but was significantly less toxic with ICs values of 1 x 10-4 M
and 5 x 10-5 M for HT10801c and HT1080scc2 respectively.
Mevinolin had no discernible detransforming effects on
HT1080scc2 cells, but was cytotoxic against both these and
the HT10801c cells with ICm values around 4 x 10-6 M for
both lines.
The most pronounced differential activity was seen with
the antibiotic, fumagillin, IC50 values obtained against the
revertant HT10801c were in the region of 8 x 10-5 M but
against the transformed HT1080scc2 line up to 50% growth
inhibition was seen at concentrations as low as 5 x 10-11 M.
Dose response curves obtained for fumagillin tended to be
biphasic and this phenomenon was particularly evident in
one of the three repeated assays carried out on this com-
pound (Figure 6). At concentrations ranging in four fold
decrements from 8 x 10-4 M to 5 x 10-5 M the cytotoxic dose
response was a steep one, but thereafter the slope was very
shallow suggestive of a sustained cytostatic effect down to
extremely low concentrations of the compound. In all three
experiments morphology of surviving cells of neither line was
affected by this drug.A CELL BASED ASSAY FOR ANTI-RAS COMPOUNDS 859
Discussion
In order to detect the effects of compounds capable of down-
regulating the transforming effects of mutated ras p21 at the
cellular level, in vitro assays employing phenotypically stable
cell lines that remain responsive to ras modulation are
required. Such lines should show readily discernible
Table I Activity of some known anti-cancer drugs and some other
selected compound against HT10801c and HT1080scc2 in vitro
(whilst IC50 values quoted at each are from a first experiment, each
was repeated at least twice giving results that did not vary signi-
ficantly from the first test i.e. not by more than plus or minus one
standard x4 dilution from the original value)
IC50(M) IC50(M)
Compound HT10801c HT1080scc2
Standard cytotoxics
Vincristine < 1.0 x 10-9 < 1.0 x 10-9
Doxorubicin 2.2 x 10-9 1.8 x 10-9
Methotrexate 3.1 x 10-8 1.1 x 10-8
6-Mercaptopurine 1.2 x 10-6 1.1 x 10-6
5-Fluorouracil 2.1 x 10-6 1.3 x 10-6
Cisplatin 5.8 x 10-6 3.4 x 10-6
Melphalan 1.2 x 10-5 1.0 x 10-5
Compound with possible
effects on ras function
Fumagillin 3.1 x 10-7 1.6 x 10-"
Mycophenolic acid 7.6 x 10-7 5.4 x 10-7a
Mevinolin 4.1 x 10-6 4.3 x 10-6
8-Bromo cAMP 8.0 x 10-5 4.8 x 10-5a
Tiazafurin 1.6 x 10-4 6.3 x 10-5a
'Cells flattened and more contact inhibited indicative of mor-
phological reversion towards HT10801c phenotype.
phenotypic differences between their transformed and their
immortalised or primary states and such differences should
be quantifiable. Preferably, the cell lines used should also be
of human origin. Growth characteristics and morphology of
HT1080scc2 were consistent with the malignant phenotype in
that the cells continued to divide after confluence, grew into
multiple layers on plastic and also formed colonies in soft
agar. HT10801c in very obvious contrast displayed contact
inhibition in culture, a much flatter morphology with few
mitotic cells seen after confluence and on inability to form
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Figure 6 Effects of fumagillin on growth of HT1080scc2 and
HT10801c clones. Note the marked cytostatic effects of the com-
pound on HT1080scc2 cells relative to its effects on the revertant
HT10801c cells.
Figure 5 Effects of 8-bromo cAMP on the morphology of HT1080scc2 and HT10801c clones. Cells in a, and b, are from untreated
HT1080scc2 and HT10801c clones respectively whilst those in c, and d, respectively are HT1080scc2 and HT10801c exposed to
0.1 millimolar 8-bromo cAMP for 4 days. Note that in c, cells have developed a phenotype similar to that of b, and d, where the
cells have a much more flattened morphology associated with cytoplasmic spreading and marked contact inhibition. Bar = 10
microns.
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colonies under anchorage independent conditions. Such clear
differences between sublines were similar to those reported
previously by Paterson et al., 1987 and were sufficiently
consistent to lend these lines for use in drug assays based on
comparative morphology and cytotoxicity. Further, the
microinjection experiments described in the present work
demonstrated clearly that the malignant phenotype of the
HT1080scc2 cells was dependent on ras expression and could
be modulated to the detransformed phenotype on neutralisa-
tion of the oncoprotein by the ras-specific Y13-259 antibody.
The susceptibility of both lines to known anti-cancer drugs
was remarkably similar and probably reflects their common
lineage. Such findings we consider important since it is well
established that human tumour cell lines of analagous but
not of homologous origin often differ greatly from one
another with regard to their response to known anti-cancer
drugs. It would indeed be potentially misleading and confus-
ing to use cells with such widely different drug-responses as
the test and control lines for identifying specific anti-ras
drugs. No selective toxicity was seen against either line and
none of the drugs induced any discernible detransforming
effects on the HT1080scc2 cells. This itself was not surprising
since these drugs are neither thought to modulate ras
oncogenes nor to induce differentiation by any other
mechanism.
Differential expression of type I and type II protein kinase
isoenzymes has been shown to affect cell growth and
differentiation (Gharret et al., 1976; Russell, 1978; Cho-
Chung, 1980) and certain analogues of c-AMP including
8-bromo cAMP have been shown to modulate this
differential expression in a spectrum of cancer cell lines (Kat-
saros et al., 1987; Ally et al., 1989). The latter authors also
showed that treatment with the compound decreased both
N-ras and c-myc mRNA levels in lung tumours. Such obser-
vations are compatable with the present results where 8-
bromo cAMP had a distinct and discernible detransforming
effect on the HT1080scc2 cells consistent with the restoration
of normal gene regulation in a ras oncogene driven tumour
cell-line in which cAMP receptor proteins play a role in
proliferation.
Inhibitors of IMP-dehydrogenase deplete guanylate levels
within cells thereby eliciting a wide variety of intracellular
effects including the down-regulation of ras oncogene expres-
sion (Olah et al., 1988). The two IMP-dehydrodgenase
inhibitors, mycophenolic acid and tiazafurin both flattened
the morphology of HT1080scc2 cells and it is speculated that
these effects may have been the result of ras downregulation.
Neither compound however was effective at non-cytotoxic
concentrations.
The post-translational farnesylation of ras proteins is an
essential prequisite for their translocation to cell membranes
(Casey et al., 1989) and the inhibition of this process through
the inhibition of HMG-CoA reductase, a key rate-limiting
enzyme in the mevalonate pathway, should result in the
depletion of membrane-associated p21. In our hands, one
such inhibitor, mevinolin, was toxic to both the transformed
and the revertant lines with no discernible detransforming
effects on HT1080scc2. Clearly inhibition of HMG-CoA
reductase could well be toxic to cells since the enzyme lies far
upstream to the protein farnesylation step. The sterol biosyn-
thetic pathway is critical for numerous cellular processes and
the cytotoxicity seen in our experiments may have been
unrelated to the post-translational modification of ras pro-
teins. Noteworthy in this context are the recent observations
of DeClue et al. (1991) who found that mevinolin was as
toxic to cells transformed by v-src or v-raf as it was against
cells transformed by v- or c-ras.
The extreme activity offumagillin against HT1080scc2 cells
deserves further investigation. This compound has anti-
tumour activity which has been associated with its anti-
angiogenic activity (Ingber et al., 1990) and it also has been
claimed (Merrimen et al., 1990) to be selectively cytotoxic in
a clonogenic assay against mouse mammary epithelial cells
transformed by K- and H-ras oncogenes. The potency of the
compound however was not as great as that displayed
against HT1080scc2 and, at least in our assays, the com-
pound appeared to be cytostatic rather than toxic, at a very
broad range of concentrations. Clearly the cytostatic effects
seen by us cannot in any way be directly associated with the
compound's known anti-angiogenic activity, and at present
we have no proof that the compound modulates ras
oncogene function.
More information is required, with regard to the response
of these two HT1080 sublines to a wider range of experi-
mental compounds, before valid conclusions can be drawn as
to their usefulness for evaluating compounds for anti-ras
activity. We recognise that unlike HT1080, the majority of
ras-associated human tumours of clinical importance are
adenocarcinomas of epithelial origin and that they usually
express K- rather than N-ras oncoproteins. Further, they
usually carry mutations at codon 12 or 13 rather than at 61
(Yanez et al., 1987). The significance of these differences is
not known. A marked degree of homology exists between K-,
N- and H-ras gene products (Barbacid, 1987) and we con-
sider that compounds designed to bind to their nucleotide
binding domains and modulate their function, are unlikely to
prove specific for any particular ras sub-type. However, it is
possible that compounds which interfere with the post-
translational modification of ras proteins might show selec-
tivity for one ras sub-type relative to another. Such, for
example, could be anticipated if a compound interfered with
the palmitoylation of p21. H- and N-ras proteins require
palmitoylation prior to their translocation to the cell memb-
rane (willumsen et al., 1984; Buss & Sefton, 1986) but K-ras
protein on the other hand does not (Hancock et al., 1989).
Despite such possible shortcomings, the HT1080scc2 and
HT10801c clones offer an unique opportunity for the screen-
ing of compounds for anti-ras activity against a human
tumour cell line where the test clone's malignancy has been
shown to be dependent on the expression of mutant ras
protein, and the non-tumourigenic control clone with its
markedly different phenotype is of the same lineage.
We thank Dr Hugh Paterson of the Institute for Cancer Research,
Chester Beatty Laboratories, Fulham Road, London SW3 6JB for
provision of the HT1080 clones and for invaluable advice on cell
microinjection techniques.
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